Inhibition of Glycolysis
Under physiological conditions healthy cells get their energy in form of ATP from mitochondrial oxidative phosphorylation. In
most tumor cells however an increased glycolysis of D-glucose for energy production known
as Warburg effect is observed. The glycolytic phenotype
of human endometrial and ovarian cancer cells can
be targeted for therapeutic intervention.
A therapy using both,
specific inhibition of glycolysis and GnRH
receptor-targeted therapy seems to be suitable for an effective strategy for treatment of above all inoperable, chemotherapy-resistant or recurring endometrial and ovarian cancers and
should be further evaluated.